HealthyPhase 1NCT00692601
The Acute Effects of Capsiate During Exercise
A Phase 1 study testing Acute consumption of Capsiate Natura in people with Healthy, run by Hamilton Health Sciences Corporation at 1 site in Canada.
Trial summary
Capsiate is a non-pungent analogue of capsaicin, the component of hot peppers that makes them hot or spicy. Unlike capsaicin, capsiate is not spicy or hot. Ingestion of capsiate has been shown to increase resting oxygen consumption, body temperature, and the burning of fat. Read more about this study
- Who is it for?
- Ages 18 to 30 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- Acute consumption of Capsiate Natura
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 12 participants
- Where
- 1 siteCanada
- Study dates
- Apr 2008to Sep 2008
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 30 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy men
- Recreationally active
- Non-smokers
- Age 18-30 years
- Favourable (low risk) answers on Standard Health Questionnaire (part of approved consent form)
- Peak VO2 of > 40 ml/kg/min
- Recruited from the local McMaster University campus or surrounding community.
Who cannot join
- Women
- Smokers
- Contraindicated health conditions which would render someone "clinically" unhealthy i.e. diabetes, liver, kidney abnormalities, etc.
- Possible allergies to the study products (Capsiate or Placebo)
- The use of foods, other natural health products or pharmaceuticals that may interact with the study products
- The use of natural health products that alter the outcome measures of the trial
Trial locations and contacts
1 site in 1 country.
Canada1 site
Exercise Metabolism Research Laboratory, McMaster Univeristy
Hamilton, Ontario, L8S 4K1
About this study
Official title: Effect of Differing Doses of A Sweet Pepper Extract - Capsiate (A Capsaicin Analogue) - On Energy Expenditure and Blood Parameters in Humans During Exercise
Capsiate is a non-pungent analogue of capsaicin, the component of hot peppers that makes them hot or spicy. Unlike capsaicin, capsiate is not spicy or hot. Ingestion of capsiate has been shown to increase resting oxygen consumption, body temperature, and the burning of fat. As such, capsiate appears to act in a manner similar to that of many other substances that energize us, increase our alertness and cause a rushing feeling by affecting a system in our body that is responsible for the release of adrenaline. The major difference, however, is that capsiate is broken down in the stomach into two components: vanilla and a fatty acid, and is not absorbed as capsiate into the blood stream at all. This implies that the way capsiate works is likely by acting on the cells in the gut (before it is broken down)rather than affecting all other cells in the body as it would do if it ended up in the blood. Therefore, the gut cells are thought to be the ones responsible for triggering the full-body adrenaline response. In any case, the use of capsiate has been shown to be effective in preventing weight gain and as such it may represent a possible therapy for treating obesity. Many obesity-related programs not involving medication advocate the use of diet and/or exercise. However, one of the biggest problems with weight loss from dieting alone is a general decrease in our body's ability to burn the food we eat as energy. This very problem is the reason for why people turn to adrenaline-releasing drugs like caffeine and ephedra. Unfortunately though, if too much is consumed, there is a high risk of bad side-effects. However, low dose caffeine/ephedra compounds (that are within specified FDA limits) have recently been reported to be effective. Moreover, these compounds are used with great frequency by people attempting to lose weight.
Given that capsiate increases body temperature, promotes the burning of body fat and has an exceptionally great side-effect profile, it looks to be a very effective supplement for use in treatment of obesity and overweight. As such, it would be important to test this supplement along with exercise. This is because consuming capsiate with exercise may enhance its effectiveness in increasing the burning of body fat. The primary purpose of this study is to examine the response of young healthy males to a 90 minute bout of moderate intensity cycling after having consumed 0 mg, 3 mg, or 10 mg of capsiate.
Read the detailed description
Hypotheses
Based on the rationale and brief background above we propose the following substantive hypotheses:
- Ingestion of capsiate 30min prior to exercise will elevate resting and exercising oxygen consumption (VO2) in a hierarchical manner: 10>3>0mg
- Respiratory exchange ratio will be shifted toward greater lipid oxidation (i.e., toward 0.7) in a hierarchical manner: 10>3>0mg
Our secondary hypotheses are:
- A greater rise in glycerol and FFA at rest and during exercise in a hierarchical manner: 10>3>0mg
- A greater rise in catecholamine (Epinephrine and Norepinephrine) concentrations in a hierarchical manner: 10>3>0mg
Protocol We will use a double-blind repeated measures study design in which subjects will complete 3 trials - 0, 3, and 10mg - of capsiate. Based on acute effects seen in previous studies 1, 4 we anticipate that a sample size of 12 subjects (all subjects will be males to control for possible sex-based differences in substrate oxidation during exercise) would appear to be adequate to see significant effects of capsiate on oxygen consumption and substrate oxidation. Randomization will be done on a counterbalanced and blocked basis with 3 conditions and 6 possible order combinations and with 12 subjects, each subject will be randomized in a counterbalanced manner so that 2 subjects complete each trial order.: ABC, ACB, BCA, BAC, CAB, CBA, order of treatment and assignment will be performed at random and under complete control of the McMaster University Pharmacy. The chief pharmacist - Dr. Gita Sobhi - will give the code for each treatment to the PI only after completion of the data analysis. We will use a cycling protocol at an intensity of 55% of each subject's individual peak VO2 for 90 minutes. Workload to determine 55% of peak VO2 will be according to the algorithm detailed by Latin et al. 17 This exercise intensity is adequate to elevate lipolysis (i.e., glycerol and FFA), catecholamines, and show a substantial shift in RER toward lipid oxidation with increasing exercise duration. The PI has experience with this protocol and has measured substrate oxidation previously using the same or very similar protocols. 18-20 Moreover, this type of exercise intensity represents an intensity that elicits an exercising RER in or around 0.9 and thus where there is a good blend (65:35 carbohydrate:lipid) of fuels being oxidized, but is also an intensity close to what has been referred to as 'fatmax', which is defined as the intensity of exercise at which the maximal rate of lipid oxidation occurs. 16, 21-23 Thus, in terms of selecting an exercise intensity that will reveal the impact of capsiate on both energy expenditure and substrate oxidation we believe that this intensity is an optimal one. We will collect breath (breath-by-breath and ensemble averaged into 30s bins) and blood samples for 30min into recovery to assess to what degree excess post-exercise oxygen consumption is elevated and whether this is accompanied by significant fat oxidation and elevated plasma catecholamines.
We will use recreationally active subjects (peak VO2 > 40 ml/kg/min) so that we're assured they will be able to complete the protocol. Subjects will be screened using a standard health questionnaire (see attached consent form) and a maximal exercise test. Subjects will be healthy non-smokers between the ages of 18-30 and will be recruited from the local McMaster University campus or surrounding community. Exercise trials will take place in the overnight fasted state (last meal at 2000h) after having consumed a standardized diet on the day prior to the exercise trial. Having subjects in the fasted state does not present a risk or barrier to the subjects completing the trial as based on past experience with this protocol. It is emphasized that being in the fasted state is also the easiest state in which to interpret the data from the standpoint of substrate oxidation. The pre-trial day diet will consist of energy estimated for each subject based on the Harris-Benedict equation 24 with an activity factor of 40%. The diet will be 50:30:20 in terms of percent energy from carbohydrate:fat:protein. Subjects will consume the same diet on the days prior to each exercise trial to control for pre-study calorie and carbohydrate/fat intake, which could affect substrate oxidation. Subjects will refrain from consumption of alcohol and caffeine on the day of the trial. Trials will take place at least 5d (but no more than 7d) apart and will commence at a time between ~7-10am and will proceed according to the schematic timeline shown in figure 1. The testing time for subjects will remain consistent throughout the study. We also believe that it is prudent for subjects to consume a fixed and constant volume of water (1000ml) during all trials to prevent dehydration and to allow subjects to complete the ride in safe manner.
All data will be analyzed using a repeated measures two-way analysis of variance with time as a within factor and dose as a between factor. Significant ANOVA effects will be further scrutinized using Tukey's test as a post-hoc procedure. Where significant correlation of one variable with another exists an analysis of covariance may also be performed. Significance will be accepted at P<0.05.
Analysis VO2 and RER for energy expenditure and substrate use - standard equations using revised non-protein RER as described by Jeukendrup and Wallis. 26 HR - using Polar™ monitoring and on-line collection via the AEI metabolic cart BP - using Finapres™ blood pressure monitoring. Blood glucose, glycerol, lactate - fluorometric methods as detailed in Passoneau and Lowry 27 and as performed previously by the PI. 18, 20, 28 Free fatty acids - colorimetric micro-assay method from WAKO diagnostics (http://www.wakodiagnostics.com/r_nefa.html) Catecholamines - using reverse phase HPLC and electrochemical detection as described previously. 18, 20
- Conditions
- Healthy
- Being tested
- Acute consumption of Capsiate Natura, Acute ingestion of identical placebo capsules
- Keywords
- Acute Exercise protocol, Crossover design, Oxygen consumption (VO2), Respiratory Exchange Ratio (RER), Adrenergic System Agonism, Capsiate Natura, Young, Male
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Acute consumption of Capsiate NaturaDietary supplement
Also called Brand: Capsiate Natura, Capsinoid
10 capsules = 3 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. 3 active capsules containing 1 mg capsiate each and 7 placebo capsules.
Acute consumption of Capsiate NaturaDietary supplement
Also called Brand: Capsiate Natura
10 capsules = 10 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate.
Acute ingestion of identical placebo capsulesDietary supplement
10 mg placebo = 0 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate.
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | acute oral ingestion of 3 mg capsiate Receives: Dietary Supplement: Acute consumption of Capsiate Natura |
| 2 | Experimental | acute oral ingestion of 10 mg capsiate Receives: Dietary Supplement: Acute consumption of Capsiate Natura |
| 3 | Placebo comparator | acute oral ingestion of 0 mg capsiate ( same number of capsules as two other trials and identical looking placebo capsules) Receives: Dietary Supplement: Acute ingestion of identical placebo capsules |
What is being measured
The primary outcome is the main question the study is designed to answer.
Respiratory Exchange Ratio (RER) for substrate use
Measured: breath by breath analysis of oxygen uptake and carbon dioxide release (recorded as the average oxygen uptake and carbon dioxide relsease every 30 seconds)
Secondary outcomes (4)
Heart Rate
Measured: measured 8 times over 180 minutes
Blood Pressure monitoring
Measured: measured 8 times over 180 minutes
Blood biomarkers (blood glucose, glycerol, lactate, Free fatty acids [FFA])
Measured: measured 6 times over 180 minutes
Plasma Catecholamines (Epinephrine, norepinephrine)
Measured: measured 6 times over 180 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jun 2008 (estimated)
- Study startApr 2008
- Primary completionJul 2008
- Study completionSep 2008
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 12 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hamilton Health Sciences Corporation
- Sponsor type
- University, hospital or other
- Collaborators
- Ajinomoto USA, INC.
- Investigators
- Stuart M Phillips, Ph.D., Principal investigator, Department of Kinesiology, McMaster UniversityAndrea R Josse, M.Sc., Study director, Department of Kinesiology, McMaster UniversityNicholas A Burd, M.Sc., Study director, Department of Kinesiology, McMaster UniversityYoshiyuki Fujishima, D.Phil., Study chair, Ajinomoto USA, INC.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00692601
- Sponsor's protocol ID
- REB 07-410
- Other IDs
- NHPD#:130269
- Status last verified
- Jun 2008
- First submitted
- 4 Jun 2008
- Last updated
- 16 Sep 2008
- Results posted
- No
- Data monitoring committee
- No
Publications
Masuda Y, Haramizu S, Oki K, Ohnuki K, Watanabe T, Yazawa S, Kawada T, Hashizume S, Fushiki T. Upregulation of uncoupling proteins by oral administration of capsiate, a nonpungent capsaicin analog. J Appl Physiol (1985). 2003 Dec;95(6):2408-15. doi: 10.1152/japplphysiol.00828.2002. Epub 2003 Sep 5.
PubMed 12959953Ohnuki K, Haramizu S, Oki K, Watanabe T, Yazawa S, Fushiki T. Administration of capsiate, a non-pungent capsaicin analog, promotes energy metabolism and suppresses body fat accumulation in mice. Biosci Biotechnol Biochem. 2001 Dec;65(12):2735-40. doi: 10.1271/bbb.65.2735.
PubMed 11826971Ohnluki K, Haramizu S, Watanabe T, Yazawa S, Fushiki T. CH-19 sweet, nonpungent cultivar of red pepper, increased body temperature in mice with vanilloid receptors stimulation by capsiate. J Nutr Sci Vitaminol (Tokyo). 2001 Aug;47(4):295-8. doi: 10.3177/jnsv.47.295.
PubMed 11767210Ohnuki K, Niwa S, Maeda S, Inoue N, Yazawa S, Fushiki T. CH-19 sweet, a non-pungent cultivar of red pepper, increased body temperature and oxygen consumption in humans. Biosci Biotechnol Biochem. 2001 Sep;65(9):2033-6. doi: 10.1271/bbb.65.2033.
PubMed 11676017
Study at a glance
From the registry record, last updated by the sponsor on 16 Sep 2008. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Differing Doses of A Sweet Pepper Extract - Capsiate (A Capsaicin Analogue) - On Energy Expenditure and Blood Parameters in Humans During Exercise
- ClinicalTrials.gov ID
- NCT00692601
- Acronym / sponsor ID
- REB 07-410
- Conditions
- Healthy
- Keywords
- Acute Exercise protocol, Crossover design, Oxygen consumption (VO2), Respiratory Exchange Ratio (RER), Adrenergic System Agonism, Capsiate Natura, Young, Male
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 12 participants (actual)
- Lead sponsor
- Hamilton Health Sciences CorporationUniversity, hospital or other
- Collaborators
- Ajinomoto USA, INC.
- Study start
- Apr 2008
- Primary completion
- Jul 2008 (actual)
- Study completion
- Sep 2008 (actual)
- First posted
- 6 Jun 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Capsiate is a non-pungent analogue of capsaicin, the component of hot peppers that makes them hot or spicy. Unlike capsaicin, capsiate is not spicy or hot. Ingestion of capsiate has been shown to increase resting oxygen consumption, body temperature, and the burning of fat. As such, capsiate appears to act in a manner similar to that of many other substances that energize us, increase our alertness and cause a rushing feeling by affecting a system in our body that is responsible for the release of adrenaline. The major difference, however, is that capsiate is broken down in the stomach into two components: vanilla and a fatty acid, and is not absorbed as capsiate into the blood stream at all. This implies that the way capsiate works is likely by acting on the cells in the gut (before it is broken down)rather than affecting all other cells in the body as it would do if it ended up in the blood. Therefore, the gut cells are thought to be the ones responsible for triggering the full-body adrenaline response. In any case, the use of capsiate has been shown to be effective in preventing weight gain and as such it may represent a possible therapy for treating obesity. Many obesity-related programs not involving medication advocate the use of diet and/or exercise. However, one of the biggest problems with weight loss from dieting alone is a general decrease in our body's ability to burn the food we eat as energy. This very problem is the reason for why people turn to adrenaline-releasing drugs like caffeine and ephedra. Unfortunately though, if too much is consumed, there is a high risk of bad side-effects. However, low dose caffeine/ephedra compounds (that are within specified FDA limits) have recently been reported to be effective. Moreover, these compounds are used with great frequency by people attempting to lose weight.
Given that capsiate increases body temperature, promotes the burning of body fat and has an exceptionally great side-effect profile, it looks to be a very effective supplement for use in treatment of obesity and overweight. As such, it would be important to test this supplement along with exercise. This is because consuming capsiate with exercise may enhance its effectiveness in increasing the burning of body fat. The primary purpose of this study is to examine the response of young healthy males to a 90 minute bout of moderate intensity cycling after having consumed 0 mg, 3 mg, or 10 mg of capsiate.
Detailed description
Hypotheses
Based on the rationale and brief background above we propose the following substantive hypotheses:
- Ingestion of capsiate 30min prior to exercise will elevate resting and exercising oxygen consumption (VO2) in a hierarchical manner: 10>3>0mg
- Respiratory exchange ratio will be shifted toward greater lipid oxidation (i.e., toward 0.7) in a hierarchical manner: 10>3>0mg
Our secondary hypotheses are:
- A greater rise in glycerol and FFA at rest and during exercise in a hierarchical manner: 10>3>0mg
- A greater rise in catecholamine (Epinephrine and Norepinephrine) concentrations in a hierarchical manner: 10>3>0mg
Protocol We will use a double-blind repeated measures study design in which subjects will complete 3 trials - 0, 3, and 10mg - of capsiate. Based on acute effects seen in previous studies 1, 4 we anticipate that a sample size of 12 subjects (all subjects will be males to control for possible sex-based differences in substrate oxidation during exercise) would appear to be adequate to see significant effects of capsiate on oxygen consumption and substrate oxidation. Randomization will be done on a counterbalanced and blocked basis with 3 conditions and 6 possible order combinations and with 12 subjects, each subject will be randomized in a counterbalanced manner so that 2 subjects complete each trial order.: ABC, ACB, BCA, BAC, CAB, CBA, order of treatment and assignment will be performed at random and under complete control of the McMaster University Pharmacy. The chief pharmacist - Dr. Gita Sobhi - will give the code for each treatment to the PI only after completion of the data analysis. We will use a cycling protocol at an intensity of 55% of each subject's individual peak VO2 for 90 minutes. Workload to determine 55% of peak VO2 will be according to the algorithm detailed by Latin et al. 17 This exercise intensity is adequate to elevate lipolysis (i.e., glycerol and FFA), catecholamines, and show a substantial shift in RER toward lipid oxidation with increasing exercise duration. The PI has experience with this protocol and has measured substrate oxidation previously using the same or very similar protocols. 18-20 Moreover, this type of exercise intensity represents an intensity that elicits an exercising RER in or around 0.9 and thus where there is a good blend (65:35 carbohydrate:lipid) of fuels being oxidized, but is also an intensity close to what has been referred to as 'fatmax', which is defined as the intensity of exercise at which the maximal rate of lipid oxidation occurs. 16, 21-23 Thus, in terms of selecting an exercise intensity that will reveal the impact of capsiate on both energy expenditure and substrate oxidation we believe that this intensity is an optimal one. We will collect breath (breath-by-breath and ensemble averaged into 30s bins) and blood samples for 30min into recovery to assess to what degree excess post-exercise oxygen consumption is elevated and whether this is accompanied by significant fat oxidation and elevated plasma catecholamines.
We will use recreationally active subjects (peak VO2 > 40 ml/kg/min) so that we're assured they will be able to complete the protocol. Subjects will be screened using a standard health questionnaire (see attached consent form) and a maximal exercise test. Subjects will be healthy non-smokers between the ages of 18-30 and will be recruited from the local McMaster University campus or surrounding community. Exercise trials will take place in the overnight fasted state (last meal at 2000h) after having consumed a standardized diet on the day prior to the exercise trial. Having subjects in the fasted state does not present a risk or barrier to the subjects completing the trial as based on past experience with this protocol. It is emphasized that being in the fasted state is also the easiest state in which to interpret the data from the standpoint of substrate oxidation. The pre-trial day diet will consist of energy estimated for each subject based on the Harris-Benedict equation 24 with an activity factor of 40%. The diet will be 50:30:20 in terms of percent energy from carbohydrate:fat:protein. Subjects will consume the same diet on the days prior to each exercise trial to control for pre-study calorie and carbohydrate/fat intake, which could affect substrate oxidation. Subjects will refrain from consumption of alcohol and caffeine on the day of the trial. Trials will take place at least 5d (but no more than 7d) apart and will commence at a time between ~7-10am and will proceed according to the schematic timeline shown in figure 1. The testing time for subjects will remain consistent throughout the study. We also believe that it is prudent for subjects to consume a fixed and constant volume of water (1000ml) during all trials to prevent dehydration and to allow subjects to complete the ride in safe manner.
All data will be analyzed using a repeated measures two-way analysis of variance with time as a within factor and dose as a between factor. Significant ANOVA effects will be further scrutinized using Tukey's test as a post-hoc procedure. Where significant correlation of one variable with another exists an analysis of covariance may also be performed. Significance will be accepted at P<0.05.
Analysis VO2 and RER for energy expenditure and substrate use - standard equations using revised non-protein RER as described by Jeukendrup and Wallis. 26 HR - using Polar™ monitoring and on-line collection via the AEI metabolic cart BP - using Finapres™ blood pressure monitoring. Blood glucose, glycerol, lactate - fluorometric methods as detailed in Passoneau and Lowry 27 and as performed previously by the PI. 18, 20, 28 Free fatty acids - colorimetric micro-assay method from WAKO diagnostics (http://www.wakodiagnostics.com/r_nefa.html) Catecholamines - using reverse phase HPLC and electrochemical detection as described previously. 18, 20
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| 1 | Experimental | Dietary Supplement: Acute consumption of Capsiate Naturaacute oral ingestion of 3 mg capsiate |
| 2 | Experimental | Dietary Supplement: Acute consumption of Capsiate Naturaacute oral ingestion of 10 mg capsiate |
| 3 | Placebo comparator | Dietary Supplement: Acute ingestion of identical placebo capsulesacute oral ingestion of 0 mg capsiate ( same number of capsules as two other trials and identical looking placebo capsules) |
Who may qualify
- Ages
- 18 to 30 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (7 listed)
- Healthy men
- Recreationally active
- Non-smokers
- Age 18-30 years
- Favourable (low risk) answers on Standard Health Questionnaire (part of approved consent form)
Key exclusion criteria (6 listed)
- Women
- Smokers
- Contraindicated health conditions which would render someone "clinically" unhealthy i.e. diabetes, liver, kidney abnormalities, etc.
- Possible allergies to the study products (Capsiate or Placebo)
- The use of foods, other natural health products or pharmaceuticals that may interact with the study products
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Acute consumption of Capsiate NaturaAlso: Brand: Capsiate Natura, Capsinoid10 capsules = 3 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. 3 active capsules containing 1 mg capsiate each and 7 placebo capsules. | Dietary supplement | 1 |
| Acute consumption of Capsiate NaturaAlso: Brand: Capsiate Natura10 capsules = 10 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate. | Dietary supplement | 2 |
| Acute ingestion of identical placebo capsules10 mg placebo = 0 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate. | Dietary supplement | 3 |
Primary outcome
Respiratory Exchange Ratio (RER) for substrate use
Time frame: breath by breath analysis of oxygen uptake and carbon dioxide release (recorded as the average oxygen uptake and carbon dioxide relsease every 30 seconds)
4 secondary outcomes
Heart Rate
Time frame: measured 8 times over 180 minutes
Blood Pressure monitoring
Time frame: measured 8 times over 180 minutes
Blood biomarkers (blood glucose, glycerol, lactate, Free fatty acids [FFA])
Time frame: measured 6 times over 180 minutes
Plasma Catecholamines (Epinephrine, norepinephrine)
Time frame: measured 6 times over 180 minutes
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Sep 2008.
- Background: PubMed 12959953Masuda Y, Haramizu S, Oki K, Ohnuki K, Watanabe T, Yazawa S, Kawada T, Hashizume S, Fushiki T. Upregulation of uncoupling proteins by oral administration of capsiate, a nonpungent capsaicin analog. J Appl Physiol (1985). 2003 Dec;95(6):2408-15. doi: 10.1152/japplphysiol.00828.2002. Epub 2003 Sep 5.
- Background: PubMed 11826971Ohnuki K, Haramizu S, Oki K, Watanabe T, Yazawa S, Fushiki T. Administration of capsiate, a non-pungent capsaicin analog, promotes energy metabolism and suppresses body fat accumulation in mice. Biosci Biotechnol Biochem. 2001 Dec;65(12):2735-40. doi: 10.1271/bbb.65.2735.
- Background: PubMed 11767210Ohnluki K, Haramizu S, Watanabe T, Yazawa S, Fushiki T. CH-19 sweet, nonpungent cultivar of red pepper, increased body temperature in mice with vanilloid receptors stimulation by capsiate. J Nutr Sci Vitaminol (Tokyo). 2001 Aug;47(4):295-8. doi: 10.3177/jnsv.47.295.
- Background: PubMed 11676017Ohnuki K, Niwa S, Maeda S, Inoue N, Yazawa S, Fushiki T. CH-19 sweet, a non-pungent cultivar of red pepper, increased body temperature and oxygen consumption in humans. Biosci Biotechnol Biochem. 2001 Sep;65(9):2033-6. doi: 10.1271/bbb.65.2033.
Related trials for Healthy
Active, not recruitingObservational study
SCIVAX: Biomarkers of Immune Dysfunction and Vaccine Responsiveness in Chronic SCI
Spinal Cord Injuries, Traumatic Spinal Cord Injury
Recruiting
Effects of a Hemp Seed-based Product on Appetite and Health Parameters
Healthy
RecruitingPhase 1
A Study of INI-822 in Healthy Volunteers and Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) or Presumed MASH
Metabolic Dysfunction-Associated Steatohepatitis
Not yet recruitingPhase 1
Phase I Trial of High-Density Theta Burst Stimulation (hdTBS)
Healthy Volunteers
Not yet recruiting
Stearic Acid and Endothelial Function
Healthy Middle-aged Subjects, Obesity & Overweight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Stuart M Phillips, Ph.D. principal investigator
Department of Kinesiology, McMaster University
Andrea R Josse, M.Sc. study director
Department of Kinesiology, McMaster University
Nicholas A Burd, M.Sc. study director
Department of Kinesiology, McMaster University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Acute consumption of Capsiate Natura in people with Healthy, run by Hamilton Health Sciences Corporation at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Sep 2008. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Respiratory Exchange Ratio (RER) for substrate use (time frame: breath by breath analysis of oxygen uptake and carbon dioxide release (recorded as the average oxygen uptake and carbon dioxide relsease every 30 seconds)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00692601, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2008.